Abstract
Background: Longitudinal item response theory (IRT) models previously suggested that the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor examination has two salient domains, tremor and nontremor, that progress in time and in response to treatment differently. Objective: Apply longitudinal IRT modeling, separating tremor and nontremor domains, to reanalyze outcomes in the previously published clinical trial (Study of Urate Elevation in Parkinson's Disease, Phase 3) that showed no overall treatment effects. Methods: We applied unidimensional and multidimensional longitudinal IRT models to MDS-UPDRS motor examination items in 298 participants with Parkinson's disease from the Study of Urate Elevation in Parkinson's Disease, Phase 3 (placebo vs. inosine) study. We separated 10 tremor items from 23 nontremor items and used Bayesian inference to estimate progression rates and sensitivity to treatment in overall motor severity and tremor and nontremor domains. Results: The progression rate was faster in the tremor domain than the nontremor domain before levodopa treatment. Inosine treatment had no effect on either domain relative to placebo. Levodopa treatment was associated with greater slowing of progression in the tremor domain than the nontremor domain regardless of inosine exposure. Linear patterns of progression were observed. Despite different domain-specific progression patterns, tremor and nontremor severities at baseline and over time were significantly correlated. Conclusions: Longitudinal IRT analysis is a novel statistical method addressing limitations of traditional linear regression approaches. It is particularly useful because it can simultaneously monitor changes in different, but related, domains over time and in response to treatment interventions. We suggest that in neurological diseases with distinct impairment domains, clinical or anatomical, this application may identify patterns of change unappreciated by standard statistical methods.
Original language | English (US) |
---|---|
Pages (from-to) | 1904-1914 |
Number of pages | 11 |
Journal | Movement Disorders |
Volume | 37 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2022 |
Funding
This work was supported by the National Institute on Aging (grants R01AG064803, P30AG072958, and P30AG028716 to S.L.). The Rush Parkinson's Disease and Movement Disorders Program is a designated Clinical Center of Excellence supported by the Parkinson Foundation. The SURE‐PD3 trial was supported by National Institutes of Health grants U01NS090259 (to M.A.S., principal investigator) and U01NS089666 (to D.O., principal investigator).
Keywords
- Bayesian modeling
- Parkinson's disease
- disease progression
ASJC Scopus subject areas
- Neurology
- Clinical Neurology